PDCD1 and cancer: Immunotherapies with checkpoint blockade antibodies targeting PD-1, PD-L1, and cytotoxic T-lymphocyte antigen 4 (CTLA-4) have remarkably improved the outcome of patients with advanced NSCLC and other cancers (Ribas and Wolchok, 2018).